Modulation of Sphingolipid Metabolism by the Phosphatidylinositol-4-phosphate Phosphatase Sac1p through Regulation of Phosphatidylinositol in Saccharomyces cerevisiae*§

Sarah E. Brice†, Charlene W. Alford‡, and L. Ashley Cowart†¶

From the †Department of Biochemistry and Molecular Biology, Medical University of South Carolina and the ‡Ralph H. Johnson Veterans Affairs Medical Center, Charleston, South Carolina 29425

Sphingolipids and phosphoinositides both play signaling roles in Saccharomyces cerevisiae. Although previous data indicate independent functions for these two classes of lipids, recent genetic studies have suggested interactions between phosphatidylinositol (PtdIns) phosphate effectors and sphingolipid biosynthetic enzymes. The present study was undertaken to further define the effects of phosphatidylinositol 4-phosphate (PtdIns(4)P) metabolism on cell sphingolipid metabolism. The data presented indicate that deletion of SAC1, a gene encoding a PtdIns(4)P phosphatase, increased levels of most sphingolipid species, including sphingoid bases, sphingoid base phosphates, and phytoceramide. In contrast, sac1Δ dramatically reduced inositol phosphophospholipids, which result from the addition of a PtdIns-derived phosphoinositol head group to ceramides through Aur1p. Deletion of SAC1 decreased PtdIns dramatically in both steady-state and pulse labeling studies, suggesting that the observed effects on sphingolipids may result from modulation of the availability of PtdIns as a substrate for Aur1p. Supporting this hypothesis, acute attenuation of PtdIns(4)P production through Sst4p immediately increased PtdIns and subsequently reduced sphingoid bases. This reduction was overcome by the inhibition of Aur1p. Moreover, modulation of sphingoid bases through perturbation of PtdIns(4)P metabolism initiated sphingolipid-dependent biological effects, supporting the biological relevance for this route of regulating sphingolipids. These findings suggest that, in addition to potential signaling effects of PtdInsP effectors on sphingolipid metabolism, PtdIns kinases may exert substantial effects on cell sphingolipid profiles at a metabolic level through modulation of PtdIns available as a substrate for complex sphingolipid synthesis.

Phosphatidylinositol-4-phosphate Phosphatase Sac1p

Saccharomyces cerevisiae

To whom correspondence should be addressed. E-mail: cowartl@musc.edu.

Supporting this hypothesis, acute attenuation of PtdIns(4)P metabolism on cell sphingolipid metabolism. The present study was undertaken to further define the effects of phosphatidylinositol 4-phosphate (PtdIns(4)P) metabolism on cell sphingolipid metabolism. The data presented indicate that deletion of SAC1, a gene encoding a PtdIns(4)P phosphatase, increased levels of most sphingolipid species, including sphingoid bases, sphingoid base phosphates, and phytoceramide. In contrast, sac1Δ dramatically reduced inositol phosphophospholipids, which result from the addition of a PtdIns-derived phosphoinositol head group to ceramides through Aur1p. Deletion of SAC1 decreased PtdIns dramatically in both steady-state and pulse labeling studies, suggesting that the observed effects on sphingolipids may result from modulation of the availability of PtdIns as a substrate for Aur1p. Supporting this hypothesis, acute attenuation of PtdIns(4)P production through Sst4p immediately increased PtdIns and subsequently reduced sphingoid bases. This reduction was overcome by the inhibition of Aur1p. Moreover, modulation of sphingoid bases through perturbation of PtdIns(4)P metabolism initiated sphingolipid-dependent biological effects, supporting the biological relevance for this route of regulating sphingolipids. These findings suggest that, in addition to potential signaling effects of PtdInsP effectors on sphingolipid metabolism, PtdIns kinases may exert substantial effects on cell sphingolipid profiles at a metabolic level through modulation of PtdIns available as a substrate for complex sphingolipid synthesis.

Phosphatidylinositol-4-phosphate Phosphatase Sac1p

Saccharomyces cerevisiae

To whom correspondence should be addressed. E-mail: cowartl@musc.edu.

† This work was supported in part by the Centers of Biomedical Research Excellence in lipidomics and pathobiology at the Medical University of South Carolina (to L. A. C.) and a Merit Review Entry Program award from the Department of Veteran’s Affairs (to L. A. C.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

‡ The on-line version of this article (available at http://www.jbc.org) contains supplemental Figs. S1–S3.

S. cerevisiae, which contains three PtdIns 4-kinases producing distinct pools of PtdIns(4)P
(5): Sst4p, which resides at the plasma membrane (16); Pik1p, which is primarily located at the Golgi (17); and Lsb6p, which is located at the plasma and vacuolar membranes (18). Notably, Sst4p is the only wortmannin-sensitive PtdIns 4-kinase in S. cerevisiae (19). Additionally, the PtdIns(4)P 5-kinase Mss4p uses PtdIns(4)P produced by Sst4p as its substrate (5). Importantly, the Sac1p lipid phosphatase, which localizes to the endoplasmic reticulum, primarily regulates the pool of PtdIns(4)P generated by Sst4p in vivo (20) (Fig. 1).

Some interactions between PtdIns pathways and sphingolipid metabolism have been probed using yeast genetic strategies, and several recent studies have focused on regulation of sphingolipid metabolic processes by PtdIns[4,5]P2 effector signaling (see Ref. 21 for review). PtdIns[4,5]P2 effectors have been

2 The abbreviations used are: DHS, dihydrosphingosine; IPC, inositol phosphoceramide; PHS, phytosphingosine; PtdIns, phosphatidylinositol; PtdIns(4)P, phosphatidylinositol 4-phosphate; PtdIns(4,5)P2, phosphatidylinositol 4,5-bisphosphate; HPLC, high pressure liquid chromatography; GFP, green fluorescent protein.
Sac1p Modulates Complex Sphingolipid Synthesis

We undertook the current study to determine whether modulating turnover of the pool of PtdIns(4)P regulated by Sac1p and Stt4p significantly impacts sphingolipid metabolism. Data evaluating turnover of the pool of PtdIns(4)P regulated by Sac1p and Stt4p; this interaction appears to occur independently of recently proposed PtdIns(4,5)P_2 effector signaling. Finally, using nutrient permease levels as a readout, it was demonstrated that these changes affect a biologically relevant pool of sphingoid bases.

Materials and Methods

Yeast Strains and Culture Conditions—The yeast strains used in this study were obtained from the Euroscarf yeast deletion library. [³H]Serine (ART 246) and [³H]inositol (0116B) were purchased from American Radiolabeled Chemicals (St. Louis, MO). Routine cultures were seeded from 5-ml overnight cultures into yeast-protease-dextrose medium, which contains 1% yeast extract, 2% proteose peptone, and 2% dextrose and grown in a water bath at 30 °C with shaking at 200–250 rpm. For routine experiments, excepting those using radioactivity, cultures were grown to mid-logarithmic phase and then aliquotted into 50-ml Falcon tubes and incubated in a water bath at 30 °C with shaking at 200–250 rpm. For heat stress, the tubes were transferred to an identical water bath at 39 °C with shaking at 200–250 rpm. Wortmannin was purchased from Calbiochem (La Jolla, CA), and aureobasidin A was purchased from Takara Bio USA (Madison, WI). The cells were treated for 10 min with wortmannin or 20 min with aureobasidin A. Myriocin was purchased from Sigma-Aldrich. The cells were treated for 5 or 15 min with myriocin, as indicated.

Sphingoid Base Measurements—After treatment as described, the cells were collected by centrifugation at 3500 × g at room temperature for 3–5 min followed by resuspension in 3 ml of 2:1 chloroform:methanol. Lipids were extracted by the method of Bligh and Dyer (24). One-third of the sample was used for total lipid phosphate determination as described previously (25). The remaining two-thirds were subjected to mild alkaline hydrolysis and resolved by HPLC as described previously (26). The peaks were quantified based on signal derived from an internal standard (l-threo-phytosphingosine).

Labeling Studies—For pulse labeling studies, the cells were grown to mid-logarithmic phase, harvested by centrifugation, and resuspended in yeast-protease-dextrose medium from
the original culture. Wortmannin (10 μg/ml) was added immediately prior to labeling as indicated. [3H]Inositol (20 μCi/ml) was added. Aliquots of 0.5 ml were taken after 10 min and pipetted into five volumes of ice-cold 10% trichloroacetic acid solution. Lipids were extracted and resolved by TLC in a solvent system of chloroform:methanol:NH₄OH (9:7:2) as described previously (27). For steady-state labeling, the cells were grown to saturation and seeded in SD complete medium containing 1 μCi/ml [3H]inositol. The cells were grown for 21 h to mid-logarithmic phase. As indicated above, aliquots of 0.5 ml were taken, and lipids were extracted and resolved by TLC. The bands visualized by this method were scraped and quantified by liquid scintillation.

**Liquid Chromatography-Mass Spectrometry Measurements**—After treatment as described, the cells were collected by centrifugation at 3500 × g at room temperature for 3–5 min, snap-frozen in an methanol/solid CO₂ bath, and analyzed as described previously (28).

**Western Blot**—The cells were grown to mid-logarithmic phase, treated as specified, harvested by centrifugation, flash-frozen, and stored at −80 °C until ready for protein isolation. Then cells were washed in 20 ml of sterile water, pelleted, resuspended in 20 mM Tris-HCl, pH 7.4, 1 mM EDTA, containing 40 μl/ml protease inhibitor mixture from Roche Applied Science. Glass beads were added to resuspended pellets, and the cells were vortexed for four periods of 30 s intercalated with 30 s on ice. The extract was centrifuged at 13,000 rpm for 10 min, and the supernatant was removed. Additional buffer was added to the extract, and the cells were again vortexed as above. The extracts were combined, and protein concentration was measured by BCA analysis using the Pierce Micro BCA protein assay kit from Fisher. Protein was adjusted to 50 μg/μl, and the samples were boiled and subsequently analyzed by Western blot using 10 μg of total protein/lane, as described previously (29). The membranes were incubated with a rabbit polyclonal anti-GFP antibody (1:1000 dilution; Santa Cruz Biotechnology) for 2 h at room temperature, washed three times with phosphate-buffered saline, and incubated for 1 h with goat anti-rabbit IgG-HRP (1:5000 dilution; Santa Cruz Biotechnology) for 2 h at room temperature, washed three times with phosphate-buffered saline, and then visualized using ECL reagents (Amersham Bioscience).

**RESULTS**

**Deletion of SAC1 Increases Sphingoid Bases**—Previous reports have demonstrated changes in sphingolipid metabolism accompanying perturbation of PtdIns metabolism (11). Additionally, phenotypic overlaps between sphingolipid and phosphoinositide metabolism mutants may indicate a functional connection. For example, altered sphingoid base levels result in defects in endocytosis and actin organization (29, 30); deletion of the PtdIns(4)P-phosphatase Sac1p also causes defects in these processes (20). To determine whether sphingolipid metabolism was altered by perturbation of PtdIns(4)P pools, sphingolipids were measured in a sac1Δ strain, which exhibits a 7–10-fold increase in PtdIns(4)P (20, 31). Deletion of SAC1 increased C₁₈ PHS over 5-fold compared with wild type cells and also significantly increased C₂₀ species (Fig. 2). These data suggested that preventing Sac1p-mediated hydrolysis of PtdIns(4)P to PtdIns increased sphingoid base levels.

**Deletion of SAC1 Does Not Increase de Novo Sphingoid Base Synthesis**—The increase in bases in sac1Δ might be attributed to either increased de novo synthesis or decreased conversion into downstream metabolites. Two complementary approaches were used to determine whether de novo synthesis was the source of the accumulation of bases observed in sac1Δ.

To assess whether the increased sphingoid bases in sac1Δ resulted from increased de novo synthesis, sphingoid bases were measured in cells treated with myriocin, a selective inhibitor of serine palmitoyltransferase (32). In the wild type, a 15-min treatment with myriocin reduced basal sphingoid bases by 65% with respect to wild type control levels (a reduction of 2.45 pmol/nmol phosphate) (Fig. 3A). Moreover, a 5-min shift to the heat stress temperature of 39 °C, which is known to increase sphingoid bases via de novo synthesis, increased total bases to 257% of controls, and this increase was completely attenuated by myriocin treatment (total bases 66% of control) (Fig. 3B). In contrast, myriocin demonstrated relatively little effect in sac1Δ, with sphingoid base levels reduced by only 16% of mutant controls after 15 min (a reduction of 1.74 pmol/nmol phosphate) (Fig. 3A). Because sac1Δ mutants maintained elevated base levels after inhibition of de novo sphingoid base synthesis, this suggests that the elevated bases derive from an alternate mechanism.

A second approach was used to verify this result. Previous work has shown that the mechanism of increasing de novo sphingolipid synthesis during heat stress involves an increased rate of uptake of media serine, which was necessary and sufficient to drive de novo sphingoid base production (33). Intriguingly, the downstream PtdIns(4,5)P₂ effectors Slm1 and Slm2 colocalize with Pma1 (34), which regulates nutrient uptake through modulation of the proton gradient at the plasma membrane (35). Therefore, it was possible that deletion of the PtdIns(4)P 4-phosphatase may increase serine uptake indirectly and, consequently, increase sphingoid base levels. However, measurement of serine uptake demonstrated the opposite
**Sac1p Modulates Complex Sphingolipid Synthesis**

Specifically, the rate of uptake of $[^{3}H]$serine in $sac1\Delta$ was only 64% of the rate in wild type cells (0.215 ± 0.015 nmol serine-10^6 cells^{-1} min^{-1} in wild type versus 0.077 ± 0.009 nmol serine-10^6 cells^{-1} min^{-1} in $sac1\Delta$) (Fig. 3C). These data may actually suggest a reduced rate of *de novo* sphingolipid synthesis in $sac1\Delta$ and, in addition to data in Fig. 3A, indicate that *de novo* synthesis does not likely mediate the increase in sphingoid bases observed in $sac1\Delta$.

**Deletion of SAC1 Increases Phytoceramide and Sphingoid Base Phosphates**—Because elevation of sphingoid bases in the $sac1\Delta$ strain did not appear to occur through *de novo* synthesis, we hypothesized that the increase in bases may result from reduced incorporation into their downstream metabolites, sphingoid base phosphates, and ceramides. Previous data indicate that inhibiting the production of individual sphingolipids can increase concentrations of neighboring metabolites. Specifically, inhibition of ceramide synthesis by $lag1\Delta$ and $lac1\Delta$ increased sphingoid base phosphates, and deletion of sphingoid base kinases increased sphingoid bases and ceramides. To determine the impact of $sac1\Delta$ on total sphingolipid profiles, lipid extracts were used for high throughput lipidomic analysis as previously described. These data indicated that, in contrast to decreased levels of downstream metabolites, $sac1\Delta$ produced little change in dihydroceramide and increased phytoceramide to 182% of wild type (Fig. 4A). Additionally, dihydrosphingosine-1-phosphate increased 27-fold, and phytosphingosine-1-phosphate increased 8-fold (Fig. 4B). These data indicate that the mechanism for increased sphingoid bases in $sac1\Delta$ does not likely involve inhibition of incorporation into immediate downstream metabolites (i.e. ceramides and/or base phosphates) and indicated an alternate mechanism for the observed sphingoid base increase.

**Deletion of SAC1 Decreases Complex Sphingolipids**—In yeast, ceramides serve as a substrate for inositol phosphorylceramide (IPC) synthesis through Aur1p. IPC then undergoes modification with mannose and an additional inositol phosphate group to generate mannosylinositol phosphorylceramide and mannosylidinositol phosphorylceramide (36). Thus, the dramatic elevation in phytoceramide levels suggested that there may be an increase in complex sphingolipids. To test this hypothesis, the cells were grown for 21 h in the presence of $[^{3}H]$inositol, and complex sphingolipids were extracted, resolved by thin layer chromatography, and quantified by liquid scintillation. Surprisingly, despite robust increases in sphingoid bases, sphingoid base phosphates, and ceramides (Figs. 2 and 4), complex sphingolipid levels decreased dramatically in $sac1\Delta$. In $sac1\Delta$ cells, IPC levels were 20% of wild type, mannosylinositol phosphorylceramide levels were 32% of wild type, and mannosylidinositol phosphorylceramide levels were 38% of wild type (Fig. 5A). This steady-state labeling study indicates a reduction in complex sphingolipid mass in $sac1\Delta$ and may suggest a slower rate of complex sphingolipid synthesis in this mutant. Therefore, a pulse labeling strategy was utilized to determine whether $sac1\Delta$ decreased the rate of flux through complex sphingolipid synthesis. The cells were incubated for 10 min in the presence of

---

5 A. L. Cowart and Y. A. Hannun, unpublished results.
[^3H]inositol, and lipids were extracted and resolved as described under “Materials and Methods.” As in the steady-state labeling experiment, pulse labeling demonstrated a decrease in complex sphingolipids in sac1/H9004 (Fig. 5B), indicating that elimination of Sac1p activity decreased both the flux and mass of complex sphingolipids.

**Inhibition of Stt4p Increases Flux through Complex Sphingolipids—**The lipid phosphatase Sac1p primarily targets the pool of PtdIns(4)P produced by Stt4p (20). To determine whether the decrease in complex sphingolipids in sac1Δ results from altered turnover of PtdIns(4)P/PtdIns, cells were treated with the Stt4p inhibitor wortmannin (19), which has been demonstrated to decrease PtdIns(4)P. The cells pulse-labeled with [^3H]inositol in the presence of wortmannin increased both IPC and mannosylinositol phosphorylceramide relative to untreated controls (Fig. 5B). Thus, inhibition of Stt4p, which decreases consumption of PtdIns for PtdIns(4)P synthesis, increased complex sphingolipids. Conversely, deletion of SAC1, which decreases regeneration of the PtdIns pool and increases PtdIns(4)P (20), decreased complex sphingolipids. Together, these results suggest that PtdIns/PtdIns(4)P dynamics through Stt4p and Sac1p impact complex sphingolipid synthesis, which may occur through modulation of PtdIns available for complex sphingolipid synthesis.

**Deletion of SAC1 Reduces PtdIns Levels—**Because complex sphingolipid synthesis requires PtdIns as a substrate (15), regulation of PtdIns levels provides one potential mechanism by which Sac1p may affect complex sphingolipid synthesis (Fig. 1). Indeed, previous data indicate that deletion of SAC1 decreased PtdIns (37). Supporting the hypothesis of a substrate level effect, steady-state labeling revealed that the sac1Δ strain, which harbors reduced complex lipids, showed labeled PtdIns levels at only 6.0% of wild type (Fig. 5C). During pulse labeling, sac1Δ decreased PtdIns by 31% of wild type, whereas treatment with the Stt4p inhibitor wortmannin increased PtdIns to 169% of wild type (Fig. 5D). These data suggest that dynamics of the Sac1p/Stt4p-mediated pool of PtdIns(4)P significantly impact cellular PtdIns levels, which raised the possibility that they impact complex sphingolipid synthesis by limiting PtdIns substrate available to Aur1p.

**Inhibition of IPC Synthase Ameliorates Reduction in Sphingoid Bases by Wortmannin—**The data strongly suggested that deleting SAC1 reduced the PtdIns available for complex sphingolipid syn-

---

*FIGURE 4. Partial sphingolipid profile of sac1Δ mutants.* The cells were grown to mid-logarithmic phase in yeast-protease-dextrose medium. The sphingolipids were extracted and measured by liquid chromatography-mass spectrometry and normalized to total phospholipids as described under “Materials and Methods.” Total lipid levels inclusive of all chain lengths are given for dihydroceramide (DHC, A) and phytoceramide and dihydrosphingosine-1-phosphate (DHS-1-P and phytosphingosine-1-phosphate (PHS-1-P, B). The results are shown as the averages of three independent cultures ± S.E. ***, p < 0.01 respective to control.

*FIGURE 5. Effects of sac1Δ and wortmannin on PtdIns and PtdIns-containing sphingolipids.* For A and C, the cells were grown to saturation and inoculated into SD medium containing [^3H]inositol. They were grown for 21 h to mid-logarithmic phase. After harvesting, the lipids were extracted and analyzed by TLC. Film was exposed to the TLC plates for 48 h. The bands visualized by TLC were scraped and counted by liquid scintillation, and molar quantities were calculated based on the proportion of radiolabeled inositol in the medium. The results are the averages of three independent cultures ± S.E. **, p < 0.01 respective to control. For B and D, the cells were grown to mid-logarithmic phase in yeast-protease-dextrose medium and resuspended in SD medium. Some were pretreated with 10 μg/ml wortmannin for 5 min as indicated. [^3H]inositol was added, and the cells were incubated for 10 min. After harvesting, the lipids were extracted and analyzed by TLC. Film was exposed to the TLC plates for 16 h (B) or 3 h (D). -- , control; +, wortmannin, Δ, sac1Δ.
Sac1p Modulates Complex Sphingolipid Synthesis

Inhibition of Stt4p Increases Nutrient Permease Levels—Because of the major defects in sphingoid base regulation in cells lacking Sac1p or Stt4p activity, it seemed likely that these cells would also harbor aberrant sphingoid base-related phenotypes. A well-established function of sphingolipids is the modulation of the levels of amino acid transporters at the plasma membrane (29, 30). Specifically, previous studies demonstrated that elevated levels of PHS inhibited nutrient import (30) and activated ubiquitin-dependent proteolysis of the uracil permease Fur4 (29). To determine the effect of altered PtdIns(4)P metabolism on permease levels, protein levels of the amino acid permease Agp2-GFP were measured. Because of potential compensatory changes in cells with a constitutive defect such as sac1Δ, protein levels were not measured in the mutant; instead, the levels were measured after acute inhibition of Stt4p or Aur1p. Strikingly, acute treatment with the Stt4p inhibitor wortmannin elevated levels of Agp2-GFP to 168% of control. On the other hand, treatment with aureobasidin A, which inhibits IPC synthesis and increases sphingoid bases, reduced protein levels to 33% of control. Cotreatment with aureobasidin A and wortmannin resulted in protein levels that were similar to control (113% of control) (Fig. 6B). These data mirror the effects of these treatments on sphingoid bases and thus indicate that manipulation of the Stt4p/Sac1p-dependent pool of PtdIns(4)P causes sphingolipid-dependent biological effects. Moreover, these changes in nutrient permease levels may explain the unexpected serine uptake data observed in both sac1Δ and wortmannin treatment (Fig. 3c and supplemental Fig. S1, respectively).

DISCUSSION

Although both anabolic and catabolic pathways of sphingolipid metabolism are well understood, mechanisms regulating these pathways or controlling flux through them remain obscure. At the same time, new roles are emerging for PtdIns, its downstream phosphorylated metabolites, and their effectors (4, 6, 8, 11, 34, 40, 41). Several lines of evidence, largely reliant on yeast genetic studies, suggest regulation of sphingolipid

This hypothesis also implies that limiting conversion of PtdIns to PtdIns(4)P, the substrate of Sac1p, which increased PtdIns (Fig. 5D), would affect sphingoid bases in the opposite manner of sac1Δ. To test this hypothesis, wortmannin, an inhibitor of the PtdIns 4-kinase Stt4p (19), was used to reduce levels of PtdIns(4)P. As predicted, acute inhibition of Stt4p activity reduced C18 PHS and DHS to 30% of the control level (Fig. 6A). It is unlikely that this reduction is due to reduced de novo sphingolipid synthesis, because serine uptake, which is both necessary and sufficient to drive de novo sphingoid base synthesis (33), increased to 139% of control with acute wortmannin treatment (supplemental Fig. S1).

If wortmannin treatment decreased sphingoid bases by increasing their conversion into ceramide and, subsequently, IPC, then cotreatment with aureobasidin A, which would prevent IPC synthesis, would be expected to abrogate the effects of wortmannin on sphingoid bases. Indeed, inhibiting utilization of PtdIns for IPC synthesis overcame the wortmannin-induced sphingoid base defect, and sphingoid bases remained at normal to elevated levels (Fig. 6A). These data further support the hypothesis that changes in PtdIns(4)P metabolism affect sphingolipid levels at least in part by altering availability of PtdIns as a substrate for Aur1p and, moreover, that attenuation of complex lipid synthesis either through decrease in PtdIns or through inhibition using aureobasidin A leads to an increase in sphingoid bases.

FIGURE 6. Aureobasidin A abrogates the effects of wortmannin on sphingoid bases and Agp2-GFP protein levels. The cells were grown at 30 °C in rich medium to mid-logarithmic phase. A, cells were pretreated with wortmannin or with aureobasidin A and grown for 5 min. The cells were harvested by centrifugation, and lipids were extracted and analyzed by HPLC as described under “Materials and Methods.” The dark gray bars represent C18 phytosphingosine; the light gray bars represent C18 dihydrosphingosine. The data presented are the averages ± S.E. of two to three independent experiments performed in triplicate. Aur A, aureobasidin A; Wm, wortmannin. B, cells were harvested by centrifugation and snap frozen. Protein was extracted, and immunoblotting was carried out as described under “Materials and Methods.” The blot shown is representative of two blots. C, control; W, wortmannin; A, aureobasidin A; A+W, aureobasidin A and wortmannin.

This concept is supported by the literature, which indicates that sphingolipid metabolism represents a highly interconnected network. In previous studies, treatment with aureobasidin A, which inhibits the IPC synthase Aur1p (38), increased ceramides while reducing levels of diacylglycerol, the other product of the IPC synthesis. This treatment increased levels of C18 PHS and DHS more than 3-fold (Fig. 6A), indicating that, indeed, attenuation of IPC synthesis caused accumulation of sphingoid bases, and raised the hypothesis that the effects on sphingoid bases in the sac1Δ mutant derived from decreased complex sphingolipid synthesis.

Thus, this hypothesis also implies that limiting conversion of PtdIns to PtdIns(4)P, the substrate of Sac1p, which increased PtdIns (Fig. 5D), would affect sphingoid bases in the opposite
Sac1p Modulates Complex Sphingolipid Synthesis

metabolism by phosphoinositides; however, no consensus has emerged about either the nature of the regulatory relationships or the mechanisms by which they occur (8–11). The purpose of this study was to determine whether substrate level interactions between the Sac1p/Stt4p pathway and Aur1p serve as a major mechanism by which PtdIns(4)P metabolism modulates sphingolipid levels.

Our data demonstrate for the first time that deletion of the gene for the lipid phosphatase SAC1 resulted in elevated sphingoid bases (Fig. 2). This accumulation did not result from increased de novo synthesis, suggesting that reduced utilization of bases for downstream metabolites may cause the observed elevation of sphingoid base levels. Deletion of SAC1 also increased levels ofphytoceramide and, dramatically, sphingoid base phosphates (Fig. 4). In contrast, complex sphingolipids were reduced in sac1Δ during both steady-state and pulse labeling (Fig. 5, A and B), indicating a reduction in both the mass of complex sphingolipids and the rate of their synthesis. PtdIns levels were reduced during both long term and pulse labeling experiments (Fig. 5, C and D), suggesting that the effects on sphingolipids may be due to reduced PtdIns availability for complex sphingolipid synthesis through Aur1p. Indeed, inhibition of Aur1p replicated the increase in sphingoid bases seen in sac1Δ mutants and overcame the decrease in bases observed in cells treated with the Stt4p inhibitor wortmannin (Fig. 6A). This further supports the hypothesis that these effects occur at the point of Aur1p-mediated inositol phosphosphingolipid synthesis.

Previous studies indicate that sphingolipid metabolism represents a highly interconnected network, and inhibiting production of many sphingolipid metabolites increases concentrations of their precursors or neighboring metabolites. The idea that a reduction in Aur1p activity can impact levels of neighboring metabolites has been explored extensively. However, to our knowledge, this is the first study to demonstrate that metabolic effects of modulation of IPC synthesis can extend beyond neighboring metabolites and upstream to sphingoid bases and sphingoid base phosphates.

Consistent with these principles, deletion of SAC1 reduced PtdIns and complex lipids while increasing upstream sphingolipid metabolites. Conversely, inhibition of Stt4p with wortmannin increased PtdIns and complex sphingolipids while decreasing sphingoid bases. The wortmannin-induced decrease in sphingoid bases was overcome by inhibition of IPC synthesis, further supporting a model in which modulation of the Stt4p/Sac1p-dependent pool of PtdIns(4)P influences sphingoid base levels via substrate supply to Aur1p. Specifically, we propose a model whereby deletion of SAC1 causes PtdIns to become sequestered as PtdIns(4)P, resulting in decreased PtdIns available for Aur1p-mediated complex sphingolipid synthesis. This block in complex sphingolipid synthesis then causes an accumulation of the metabolic precursor for IPC synthesis, ceramide, and its metabolic precursors, sphingoid bases.

One challenge to this model comes in the alternative hypothesis that Isc1p, which catabolizes IPC to generate ceramides (42), caused the changes in complex lipid levels. However, levels of α-HO phytotherceramide, the product of Isc1p (43), are reduced to 27% of wild type in sac1Δ (supplemental Fig. S2). Indeed, the overall ceramide profile in sac1Δ mutants (Fig. 4a and supplemental Fig. S2) does not reflect the whole cell profile expected for cells with elevated ISc1p activity (43), discounting the idea that ISc1p activity decreased complex sphingolipids in this mutant. Additionally, altered ISc1p activity would not explain the dramatic decrease in PtdIns observed in sac1Δ (Fig. 5, C and D). Together, these data support Aur1p, rather than ISc1p, as the key enzyme in this interaction.

One mechanism by which deletion of SAC1 may limit substrate availability to IPC synthesis is the direct sequestration of PtdIns as PtdIns(4)P. Previously, it has been shown that dramatic alterations in phosphoinositide profiles occur when PtdIns(4)P turnover is perturbed with sac1Δ; indeed, the proportion of PtdIns(4)P increases to 12–24% of labeled phosphoinositides, a 7–10-fold change (20, 31). The Km of Aur1p is 5 mol% PtdIns (44), and the concentration of PtdIns in the cell is 4.6 mol% during the exponential growth phase (45). The magnitude of these changes lends credence to the notion that altering PtdIns(4)P levels can modulate PtdIns to an extent that would significantly impact complex sphingolipid synthesis. Additionally, the reduced turnover of PtdIns(4)P to PtdIns is thought to contribute significantly to the inositol auxotrophy of sac1Δ mutants (46); this further supports the idea that changes in Sac1p/Stt4p function can directly alter cellular PtdIns levels. In this model, decreased turnover of PtdIns(4)P to PtdIns by sac1Δ would reduce complex sphingolipid synthesis by sequestering PtdIns in PtdIns(4)P and downstream metabolites; this would result in a buildup of ceramides and sphingoid bases.

In contrast to the mechanism proposed here, several recent studies have described regulation of sphingolipid metabolism by PtdIns(4,5)P2 effectors, particularly through Slm1p and calcineurin (8, 10, 11). Significantly, total sphingoid base levels were virtually unaltered in single-deletion mutants for SLM1, SLM2, and the calcineurin regulatory subunit CNB1 (supplemental Fig. S3), suggesting that the effect on sphingoid bases in sac1Δ does not occur primarily through known PtdIns(4,5)P2-dependent signaling pathways. Additionally, other observations in sac1Δ mutants and wortmannin-treated cells do not correspond to the described effects of PtdIns(4,5)P2 effector-mediated regulation. For example, it has been proposed that Slm1/2p regulate IPC levels by inhibiting ISc1p, which catabolizes IPC (11). Thus, a reduction in PtdIns(4,5)P2 levels consequent to Stt4p inhibition would be expected to relieve the inhibition of ISc1p by Slm1/2p, decreasing complex sphingolipid levels. However, acute wortmannin treatment was shown to increase these levels (Fig. 5B). Additionally, a previous study demonstrated very little change in PtdIns(4,5)P2 levels in sac1Δ (31), making altered Slm1/2p activity an unlikely source of its effects. Likewise, it has been proposed that calcineurin inhibits ceramide synthesis (9) and that calcineurin is itself inhibited by Slm1/2p (11). Wortmannin-treated cells, which produce less PtdIns(4,5)P2, thus would be thought to have less Slm1/2p activity. This would increase calcineurin activity, leading to reduced ceramide synthesis and, most likely, reduced complex sphingolipids and increased sphingoid bases. However, this is the opposite of what is observed in Stt4p-inhibited cells (Figs. 5C and 6A). The corresponding predictions for sac1Δ similarly fail to describe the data obtained in these studies. Thus, although PtdIns(4,5)P2 effector pathways provide an important
mode of sphingolipid regulation, the effects described in the present study occur through an independent mechanism.

A key question for this study is whether the changes in sphingolipid levels, especially sphingoid bases, have any biological relevance in the cell. One established readout of sphingoid base-mediated effects involves nutrient permeases. Specifically, increased phytosphingosine reduces nutrient import (30) and levels of nutrient permeases (29, 30). Intriguingly, serine uptake was reduced in sac1Δ mutants and increased in wortmannin-treated cells. Indeed, sac1Δ mutants took up serine at 64% of the rate of wild type (Fig. 3C), whereas inhibition of Stt4p with wortmannin increased serine uptake to 139% of control (supplementary Fig. S1). This suggested the possibility that the drastic elevation of sphingoid bases in sac1Δ resulted in an increased rate of permease degradation, thus decreasing levels of permeases, whereas the reduced sphingoid bases observed upon inhibition of Stt4p would allow an increase in permease levels. To test this hypothesis, protein levels of the nutrient permease App2-GFP were measured by immunoblot in cells treated acutely with wortmannin or aureobasidin A. Consistent with this hypothesis, inhibition of Stt4p led to levels of App2-GFP that were 168% of control (Fig. 6B), whereas inhibition of IPC synthesis decreased protein levels to 33% of control (Fig. 6B). Inhibition of both Stt4p and Aur1p, which overcomes the effect of wortmannin on sphingoid bases, resulted in protein levels similar to control (113% of control). Potentially, this may indicate a negative feedback loop in which increased sphingoid base levels decrease serine uptake and thus reduce the rate of de novo sphingolipid synthesis; reduced sphingoid base levels would have the opposite effect. More concretely, these results suggest that alterations in sphingolipid levels by perturbation of PtdIns pathways affect biologically active pools of sphingoid bases. This implies that future studies perturbing key PtdIns metabolizing enzymes should consider potential sphingolipid-mediated effects when interpreting phenotypic changes in these systems.

Topology also poses a significant issue in the resolution of the relationships between Stt4p, Sac1p, and complex sphingolipid metabolism. Indeed, Stt4p localizes to the plasma membrane (16), whereas Sac1p localizes primarily to the endoplasmic reticulum (20). The substrate level relationship between these two enzymes is well established (20), but the mechanism of PtdIns(4,5)P₂ transport from the plasma membrane to the binding site of Sac1p remains unclear. Likewise, this study does not address the very important issue of transport between the PtdIns pool supplying Aur1p, which localizes to the Golgi (47), and those pools associated with Stt4p and Sac1p. However, sphingolipid metabolism is distributed across multiple organelles. Additionally, there are multiple known PtdIns transport proteins (48); this supports the possibility of phospholipid transport between cellular compartments for sphingolipid synthesis.

The decrease in complex sphingolipids in sac1Δ and increased complex sphingolipids with acute wortmannin treatment contrast data from a previous study that showed reduced complex sphingolipids in stt4Δ (11). However, in our hands the background strain from that study produced an unusual sphingolipid profile and a highly depressed heat stress response (data not shown). Additionally, the sphingolipid profile of the stt4Δ mutant was altered at permissive as well as restrictive temperature (Ref. 11 and data not shown). The constitutive reduction of function of Stt4p, which is a vital protein, may induce changes in sphingolipid levels via signaling through Slm1/2, calcineurin, and TORC2 (9, 11); these effects may not be as pronounced at early time points with acute inhibitor treatment and would not be predicted to occur in sac1Δ, in which PtdIns(4,5)P₂ levels remain virtually unchanged (31). Finally, to use temperature-sensitive mutants, Tabuchi et al. (11) evaluated sphingolipids under heat stress conditions. It has been shown extensively that sphingolipid levels are drastically altered in response to heat stress conditions (reviewed in Ref. 1), and lipid levels during heat stress may not correspond to what would be seen with the same disruptions under nonstress conditions.

Still unknown are possible substrate effects through other PtdIns kinases. However, it has previously been shown that dysregulation of the PtdIns-4-kinase Pik1p does not appear to affect sphingolipid levels (11). This suggests that consumption and regeneration of the Stt4p/Sac1p-dependent pool of PtdIns(4)P holds a unique importance for sphingolipid metabolism.

In conclusion, in addition to putative interplay between PtdIns(4,5)P₂ effectors and sphingolipid metabolism, the data indicate that Sac1p and Stt4p activity have substantial metabolic effects on sphingolipid levels via modulation of substrate supply to Aur1p. This substrate level effect occurs independently of known PtdInsP effector signaling and appears to outweigh signaling through Slm1/2p and calcineurin in this context. Finally, the present study provides an important caveat to the interpretation of experiments that interfere with phosphatidylinositol phosphate metabolism, and, in light of these data, it must be considered which phenotypes are due to altered sphingolipid levels and which ones are attributable to bona fide phosphatidylinositol phosphate signaling.

Acknowledgments—We thank Dr. Jacek Bielawski and the lipidomics core facility at MLISC. We also thank Dr. Yusuf Hannun and Dr. Hiroko Hama for invaluable discussion and insight.

REFERENCES

1. Dickson, R. C., Sumanasekera, C., and Lester, R. L. (2006) Prog. Lipid Res. 45, 447–465
2. Obied, L. M., Okamoto, Y., and Mao, C. (2002) Biochim. Biophys. Acta 1585, 163–171
3. Sims, K. J., Spassieva, S. D., Voit, E. O., and Obied, L. M. (2004) Biochem. Cell Biol. 82, 45–61
4. Cameroni, E., De Virgilio, C., and Deloche, O. (2006) J. Biol. Chem. 281, 38139–38149
5. Audhya, A., Foti, M., and Emr, S. D. (2000) Mol. Biol. Cell 11, 2673–2689
6. Muhua, L., Adames, N. R., Murphy, M. D., Shields, C. R., and Cooper, J. A. (1998) Nature 393, 487–491
7. Desrivieres, S., Cooke, F. T., Morales-Johansson, H., Parker, P. J., and Hall, M. N. (2002) Biochem. J. 366, 945–951
8. Bultynck, G., Heath, V. L., Majeed, A. P., Galan, J. M., Hguenauer-Tsapis, R., and Cyert, M. S. (2006) Mol. Cell. Biol. 26, 4729–4745
9. Aronova, S., Wedaman, K., Aronov, P. A., Fontes, K., Ramos, K., Hambrock, B. D., and Powers, T. (2008) Cell Metab. 7, 148–158
10. Daquinag, A., Fadri, M., Jung, S. Y., Qin, J., and Kunz, J. (2007) Mol. Cell. Biol. 27, 633–650
Sac1p Modulates Complex Sphingolipid Synthesis

11. Tabuchi, M., Audhya, A., Parsons, A. B., Boone, C., and Emr, S. D. (2006) Mol. Cell. Biol. 26, 5861–5875
12. Pinto, W. J., Wells, G. W., and Lester, R. L. (1992) J. Bacteriol. 174, 2575–2581
13. Nagiec, M. M., Krzypiec, M., Nagiec, E. E., Lester, R. L., and Dickson, R. C. (1998) J. Biol. Chem. 273, 19437–19442
14. Wells, G. B., Dickson, R. C., and Lester, R. L. (1998) J. Biol. Chem. 273, 7235–7243
15. Lester, R. L., and Dickson, R. C. (1993) Adv. Lipid Res. 26, 253–274
16. Audhya, A., and Emr, S. D. (2002) Dev. Cell 2, 593–605
17. Walch-Solimena, C., and Novick, P. (1999) Nat. Cell Biol. 1, 523–525
18. Han, G. S., Audhya, A., Markley, D. J., Emr, S. D., and Carman, G. M. (2002) J. Biol. Chem. 277, 47709–47718
19. Cutler, N. S., Heitman, J., and Cardenas, M. E. (1997) J. Biol. Chem. 272, 27671–27677
20. Foti, M., Audhya, A., and Emr, S. D. (2001) Mol. Biol. Cell 12, 2396–2411
21. Dickson, R. C. (2008) J. Lipid Res. 49, 909–921
22. Alvarez-Vazquez, F., Simas, K. J., Cowart, L. A., Okamoto, Y., Voit, E. O., and Hannun, Y. A. (2005) Nature 433, 425–430
23. Cerbon, J., Falcon, A., Hernandez-Luna, C., and Segura-Cobos, D. (2005) Biochem. J. 388, 169–176
24. Bligh, E. G., and Dyer, W. J. (1959) Can J. Biochem. Physiol. 37, 911–917
25. Saheki, S., Takeda, A., and Shimazu, T. (1985) Anal. Biochem. 148, 277–281
26. Merrill, A. H., Jr., Wang, E., Mullins, R. E., Jamison, W. C., Nimkar, S., and Liotta, D. C. (1988) Anal. Biochem. 171, 373–381
27. Mao, C., Wu, W. I., Nickels, J. T., Jr., Ko, J., Fischl, A. S., Vales, T. R., Merrill, A. H., Jr., and Bankaitis, V. A. (1995) Mol. Biol. Cell 10, 2235–2250
28. Cutler, N. S., Heitman, J., and Cardenas, M. E. (1997) J. Biol. Chem. 272, 27671–27677
29. Chung, N., Jenkins, G., Hannun, Y. A., Heitman, J., and Obeid, L. M. (2000) J. Biol. Chem. 275, 17229–17232
30. Chung, N., Mao, C., Heitman, J., Hannun, Y. A., and Obeid, L. M. (2001) J. Biol. Chem. 276, 35614–35621
31. Tahirovic, S., Schorr, M., and Mayinger, P. (2005) Traffic 6, 116–130
32. Miyake, Y., Kozutsumi, Y., Nakamura, S., Fujita, T., and Kawasaki, T. (1995) Biochem. Biophys. Res. Commun. 211, 396–403
33. Cotter, L. A., and Hannun, Y. A. (2007) J. Biol. Chem. 282, 12330–12340
34. Fadri, M., Daquinag, A., Wang, S., Xue, T., and Kunz, J. (2005) Mol. Biol. Cell 16, 1883–1900
35. Syhrova, H., and Kotyk, A. (1985) FEBS Lett. 183, 21–24
36. Smith, E. R., and Merrill, A. H., Jr. (1995) J. Biol. Chem. 270, 13171–13178
37. Hama, H., Schnieders, E. A., Thorner, J., Takemoto, J. Y., and DeWald, D. B. (1999) J. Biol. Chem. 274, 34294–34300
38. Heidler, S. A., and Radding, J. A. (1995) Antimicrob. Agents Chemother. 39, 2765–2769
39. Loewen, C. J., Gaspar, M. L., Jesch, S. A., Delon, C., Kistakis, N. T., Henry, S. A., and Levine, T. P. (2004) Science 304, 1644–1647
40. Choi, J. Y., Riekhof, W. R., Wu, W. I., and Voelker, D. R. (2006) Biochem. Soc. Trans. 34, 404–408
41. Routt, S. M., Ryan, M. M., Tyeryar, K., Rizzieri, K. E., Mousley, C., Roumanie, O., Brennwald, P. J., and Bankaitis, V. A. (2005) Traffic 6, 1157–1172
42. Sawai, H., Okamoto, Y., Luberto, C., Mao, C., Bielawska, A., Domae, N., and Hannun, Y. A. (2000) J. Biol. Chem. 275, 39793–39798
43. Kitagaki, H., Cowart, L. A., Matmati, N., Vaena de Avalos, S., Novgorodov, S. A., Zeidan, Y. H., Bielawski, J., Obeid, L. M., and Hannun, Y. A. (2007) Biochim. Biophys. Acta 1768, 2849–2861
44. Fischl, A. S., Liu, Y., Browdy, A., and Cremesti, A. E. (2000) Methods Enzymol. 311, 123–130
45. Wu, W. I., McDonough, V. M., Nickels, J. T., Jr., Ko, J., Fischl, A. S., Vales, T. R., Merrill, A. H., Jr., and Carman, G. M. (1995) J. Biol. Chem. 270, 13171–13178
46. Rivas, M. P., Kearns, B. G., Xie, Z., Guo, S., Sekar, M. C., Hosaka, K., Kagiwada, S., York, J. D., and Bankaitis, V. A. (1999) Mol. Biol. Cell 10, 2235–2250
47. Levine, T. P., Wiggins, C. A., and Munro, S. (2000) Mol. Biol. Cell 11, 2267–2281
48. Mousley, C. J., Tyeryar, K. R., Ryan, M. M., and Bankaitis, V. A. (2006) Biochem. Soc Trans 34, 346–350